PetVivo Holdings develops and commercializes veterinary medical devices and biomedical therapeutics for companion animals and equines through PetVivo Animal Health and PetVivo AI. Its recurring company updates center on Spryng with OsteoCushion Technology, a veterinarian-administered intra-articular injection for joint-related conditions including lameness and osteoarthritis, and PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinary use.
News also covers regulatory acknowledgements, product availability, licensing and commercialization activity, PetVivo.ai and AgenticPet AI technology, fiscal results, conference presentations, and capital-market communications. The company describes a strategy of applying human therapies to animal health and protects its biomaterials, products, production processes and methods of use through patents and trade secrets.
PetVivo Holdings, Inc. (OTCQB: PETV) has announced the appointment of Robert J. Folkes as its new Chief Financial Officer. Folkes, with extensive experience in medical device firms, previously held key roles at Tactile Systems Technology and Advanced Respiratory. CEO John Lai expressed excitement about Folkes' expertise contributing to the company's mission to develop innovative therapeutics for pets. PetVivo is focused on commercializing unique medical devices, including its lead product, Kush, aimed at treating osteoarthritis in animals.
PetVivo Holdings (OTCQB: PETV) has opened a new medical device manufacturing facility and Center of Excellence in Edina, Minnesota, aimed at producing its veterinary medical device, KUSH™, for osteoarthritis treatment. This facility can manufacture up to 500,000 syringes of KUSH, potentially generating over $100 million annually. The site features advanced cleanroom spaces and skilled staffing to ensure efficient production and product development. The opening enhances PetVivo's commercial capabilities and control over its intellectual property, paving the way for future innovations.